Drug Trial Radar · NCT07930039
A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
May 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, randomized, double-blind, placebo-controlled clinical trial of multiple subcutaneous administrations of GR2301 Injection to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics in trial participants with vitiligo. Eligible trial participants will be randomized using stratified block randomization, with competitive enrollment across sites; they will be assigned to the experimental group or the control group in the order of successful screening.
Conditions
- Vitiligo
Interventions
GR2301 injectionBiological
IL15 monoclonal antibody
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of trial participants achieving F-VASI50 at the Week 24 (W24) visit.Time frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.